Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

Carla Zoja, Daniela Corna, Valeria Nava, Monica Locatelli, Mauro Abbate, Flavio Gaspari, Fabiola Carrara, Fabio Sangalli, Giuseppe Remuzzi, Ariela Benigni

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Bardox-olone methyl is an antioxidant inflammation modulator acting through induction of Keap1-Nrf2 pathway. Results from a recent phase IIb clinical trial reported that bardoxolone methyl was associated with improvement in the estimated glomerular filtration rate in patients with advanced chronic kidney disease and Type 2 diabetes. However, increases in albuminuria, serum transaminase, and frequency of adverse events were noted. We studied the effect of 3-mo treatment with RTA 405, a synthetic triterpenoid analog of bardoxolone methyl in Zucker diabetic fatty rats with overt Type 2 diabetes. Rats were treated from 3 mo of age with vehicle, RTA 405, ramipril, or RTA 405 plus ramipril. RTA 405 caused severe changes in food intake and diuresis with decline in body weight, worsening of dyslipidemia, and increase in blood pressure. Early elevation in serum transaminase was followed by liver injury. RTA 405 worsened proteinuria, glomerulo-sclerosis, and tubular damage. Ramipril was renoprotective, but when given with RTA 405 it was not able to limit its worsening effects. These data could be due to degradation products in the drug substance used, as disclosed by the company once the study was concluded. To overcome such a drawback, the company offered to test dh404, a variant of RTA 405, in Zucker diabetic fatty rats. The dh404 did not display beneficial effects on proteinuria, glomerulosclerosis, and interstitial inflammation. Rather, kidneys from three rats receiving dh404 showed the presence of a granulomatous and inflammatory process reminiscent of a pseudotumor. Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume304
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Diabetic Nephropathies
Ramipril
Transaminases
Proteinuria
Type 2 Diabetes Mellitus
Inflammation
Albuminuria
Diuresis
Sclerosis
Dyslipidemias
2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate
Serum
Glomerular Filtration Rate
Chronic Renal Insufficiency
Eating
Antioxidants
Body Weight
Clinical Trials
Blood Pressure

Keywords

  • Dh404
  • Diabetic nephropathy
  • Liver toxicity
  • Renal injury
  • RTA 405
  • Zucker diabetic fatty rats

ASJC Scopus subject areas

  • Physiology
  • Urology
  • Medicine(all)

Cite this

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. / Zoja, Carla; Corna, Daniela; Nava, Valeria; Locatelli, Monica; Abbate, Mauro; Gaspari, Flavio; Carrara, Fabiola; Sangalli, Fabio; Remuzzi, Giuseppe; Benigni, Ariela.

In: American Journal of Physiology - Renal Physiology, Vol. 304, No. 6, 2013.

Research output: Contribution to journalArticle

@article{319ab705a8d64b928927e7add81cf494,
title = "Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects",
abstract = "Bardox-olone methyl is an antioxidant inflammation modulator acting through induction of Keap1-Nrf2 pathway. Results from a recent phase IIb clinical trial reported that bardoxolone methyl was associated with improvement in the estimated glomerular filtration rate in patients with advanced chronic kidney disease and Type 2 diabetes. However, increases in albuminuria, serum transaminase, and frequency of adverse events were noted. We studied the effect of 3-mo treatment with RTA 405, a synthetic triterpenoid analog of bardoxolone methyl in Zucker diabetic fatty rats with overt Type 2 diabetes. Rats were treated from 3 mo of age with vehicle, RTA 405, ramipril, or RTA 405 plus ramipril. RTA 405 caused severe changes in food intake and diuresis with decline in body weight, worsening of dyslipidemia, and increase in blood pressure. Early elevation in serum transaminase was followed by liver injury. RTA 405 worsened proteinuria, glomerulo-sclerosis, and tubular damage. Ramipril was renoprotective, but when given with RTA 405 it was not able to limit its worsening effects. These data could be due to degradation products in the drug substance used, as disclosed by the company once the study was concluded. To overcome such a drawback, the company offered to test dh404, a variant of RTA 405, in Zucker diabetic fatty rats. The dh404 did not display beneficial effects on proteinuria, glomerulosclerosis, and interstitial inflammation. Rather, kidneys from three rats receiving dh404 showed the presence of a granulomatous and inflammatory process reminiscent of a pseudotumor. Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy.",
keywords = "Dh404, Diabetic nephropathy, Liver toxicity, Renal injury, RTA 405, Zucker diabetic fatty rats",
author = "Carla Zoja and Daniela Corna and Valeria Nava and Monica Locatelli and Mauro Abbate and Flavio Gaspari and Fabiola Carrara and Fabio Sangalli and Giuseppe Remuzzi and Ariela Benigni",
year = "2013",
doi = "10.1152/ajprenal.00376.2012",
language = "English",
volume = "304",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

AU - Zoja, Carla

AU - Corna, Daniela

AU - Nava, Valeria

AU - Locatelli, Monica

AU - Abbate, Mauro

AU - Gaspari, Flavio

AU - Carrara, Fabiola

AU - Sangalli, Fabio

AU - Remuzzi, Giuseppe

AU - Benigni, Ariela

PY - 2013

Y1 - 2013

N2 - Bardox-olone methyl is an antioxidant inflammation modulator acting through induction of Keap1-Nrf2 pathway. Results from a recent phase IIb clinical trial reported that bardoxolone methyl was associated with improvement in the estimated glomerular filtration rate in patients with advanced chronic kidney disease and Type 2 diabetes. However, increases in albuminuria, serum transaminase, and frequency of adverse events were noted. We studied the effect of 3-mo treatment with RTA 405, a synthetic triterpenoid analog of bardoxolone methyl in Zucker diabetic fatty rats with overt Type 2 diabetes. Rats were treated from 3 mo of age with vehicle, RTA 405, ramipril, or RTA 405 plus ramipril. RTA 405 caused severe changes in food intake and diuresis with decline in body weight, worsening of dyslipidemia, and increase in blood pressure. Early elevation in serum transaminase was followed by liver injury. RTA 405 worsened proteinuria, glomerulo-sclerosis, and tubular damage. Ramipril was renoprotective, but when given with RTA 405 it was not able to limit its worsening effects. These data could be due to degradation products in the drug substance used, as disclosed by the company once the study was concluded. To overcome such a drawback, the company offered to test dh404, a variant of RTA 405, in Zucker diabetic fatty rats. The dh404 did not display beneficial effects on proteinuria, glomerulosclerosis, and interstitial inflammation. Rather, kidneys from three rats receiving dh404 showed the presence of a granulomatous and inflammatory process reminiscent of a pseudotumor. Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy.

AB - Bardox-olone methyl is an antioxidant inflammation modulator acting through induction of Keap1-Nrf2 pathway. Results from a recent phase IIb clinical trial reported that bardoxolone methyl was associated with improvement in the estimated glomerular filtration rate in patients with advanced chronic kidney disease and Type 2 diabetes. However, increases in albuminuria, serum transaminase, and frequency of adverse events were noted. We studied the effect of 3-mo treatment with RTA 405, a synthetic triterpenoid analog of bardoxolone methyl in Zucker diabetic fatty rats with overt Type 2 diabetes. Rats were treated from 3 mo of age with vehicle, RTA 405, ramipril, or RTA 405 plus ramipril. RTA 405 caused severe changes in food intake and diuresis with decline in body weight, worsening of dyslipidemia, and increase in blood pressure. Early elevation in serum transaminase was followed by liver injury. RTA 405 worsened proteinuria, glomerulo-sclerosis, and tubular damage. Ramipril was renoprotective, but when given with RTA 405 it was not able to limit its worsening effects. These data could be due to degradation products in the drug substance used, as disclosed by the company once the study was concluded. To overcome such a drawback, the company offered to test dh404, a variant of RTA 405, in Zucker diabetic fatty rats. The dh404 did not display beneficial effects on proteinuria, glomerulosclerosis, and interstitial inflammation. Rather, kidneys from three rats receiving dh404 showed the presence of a granulomatous and inflammatory process reminiscent of a pseudotumor. Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy.

KW - Dh404

KW - Diabetic nephropathy

KW - Liver toxicity

KW - Renal injury

KW - RTA 405

KW - Zucker diabetic fatty rats

UR - http://www.scopus.com/inward/record.url?scp=84877930774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877930774&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00376.2012

DO - 10.1152/ajprenal.00376.2012

M3 - Article

VL - 304

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 6

ER -